{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:21:29Z","timestamp":1790749289919,"version":"4.1.0"},"reference-count":195,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Huntington\u2019s disease (HD) is an autosomal dominant neurodegenerative disorder caused by pathogenic expansions of the triplet cytosine-adenosine-guanosine (CAG) within the Huntingtin gene. These expansions lead to a prolongation of the poly-glutamine stretch at the N-terminus of Huntingtin causing protein misfolding and aggregation. Huntingtin and its pathological variants are widely expressed, but the central nervous system is mainly affected, as proved by the wide spectrum of neurological symptoms, including behavioral anomalies, cognitive decline and motor disorders. Other hallmarks of HD are loss of body weight and muscle atrophy. This review highlights some key elements that likely provide a major contribution to muscle atrophy, namely, alteration of the transcriptional processes, mitochondrial dysfunction, which is strictly correlated to loss of energy homeostasis, inflammation, apoptosis and defects in the processes responsible for the protein quality control. The improvement of muscular symptoms has proven to slow the disease progression and extend the life span of animal models of HD, underlining the importance of a deep comprehension of the molecular mechanisms driving deterioration of muscular tissue.<\/jats:p>","DOI":"10.3390\/ijms21218314","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T19:38:41Z","timestamp":1604605121000},"page":"8314","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Molecular Mechanisms Underlying Muscle Wasting in Huntington\u2019s Disease"],"prefix":"10.3390","volume":"21","author":[{"given":"Manuela","family":"Bozzi","sequence":"first","affiliation":[{"name":"Dipartimento Universitario di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Sezione di Biochimica e Biochimica Clinica, Universit\u00e0 Cattolica del Sacro Cuore di Roma, Largo F. Vito 1, 00168 Roma, Italy"},{"name":"Istituto di Scienze e Tecnologie Chimiche \u201cGiulio Natta\u201d\u2013 SCITEC Sede di Roma, Largo F. Vito 1, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Sciandra","sequence":"additional","affiliation":[{"name":"Istituto di Scienze e Tecnologie Chimiche \u201cGiulio Natta\u201d\u2013 SCITEC Sede di Roma, Largo F. Vito 1, 00168 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15916","DOI":"10.1074\/jbc.M511007200","article-title":"Expression and characterization of full-length human huntingtin, an elongated HEAT repeat protein","volume":"281","author":"Li","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/molbev\/msm258","article-title":"Phylogenetic comparison of huntingtin homologues reveals the appearance of a primitive PolyQ in sea urchin","volume":"25","author":"Tartari","year":"2008","journal-title":"Mol. Biol. Evol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ng1095-155","article-title":"Increased apoptosis and early embryonic lethality in mice nullizygous for the huntington\u2019s disease gene homologue","volume":"11","author":"Zeitlin","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neuron.2012.05.024","article-title":"Network organization of the huntingtin proteomic interactome in mammalian brain","volume":"75","author":"Shirasaki","year":"2012","journal-title":"Neuron"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nn.4256","article-title":"Integrated genomics and proteomics define huntingtin cag length-dependent networks in mice","volume":"19","author":"Langfelder","year":"2016","journal-title":"Nat. Neurosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of Huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1136\/jmg.30.12.982","article-title":"Gametic but not somatic instability of CAG repeat length in Huntington\u2019s disease","volume":"30","author":"MacDonald","year":"1993","journal-title":"J. Med. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/35039051","article-title":"Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease","volume":"1","author":"Gusella","year":"2000","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1146\/annurev.neuro.29.051605.113042","article-title":"Trinucleotide repeat disorders","volume":"30","author":"Orr","year":"2007","journal-title":"Annu. Rev. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJM199405193302001","article-title":"A worldwide study of the Huntington\u2019s disease mutation: The sensitivity and specificity of measuring CAG repeats","volume":"330","author":"Kremer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","article-title":"Polyglutamine repeats in neurodegenerative diseases","volume":"14","author":"Lieberman","year":"2019","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jnc.14853","article-title":"The pathobiology of perturbed mutant huntingtin protein\u2013protein interactions in Huntington\u2019s disease","volume":"151","author":"Wanker","year":"2019","journal-title":"J. Neurochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nature02998","article-title":"Inclusion body formation reduces levels of mutant Huntingtin and the risk of neuronal death","volume":"431","author":"Arrasate","year":"2004","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1523\/JNEUROSCI.21-06-01830.2001","article-title":"Tissue-specific proteolysis of Huntingtin (Htt) in human brain: Evidence of enhanced levels of N-and C-terminal Htt fragments in Huntington\u2019s disease striatum","volume":"21","author":"Toneff","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.22-18-07862.2002","article-title":"Caspase cleavage of mutant Huntingtin precedes neurodegeneration in Huntington\u2019s disease","volume":"22","author":"Wellington","year":"2002","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1093\/hmg\/ddn175","article-title":"Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in huntington\u2019s disease","volume":"17","author":"Wang","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neuron.2010.06.021","article-title":"Matrix metalloproteinases are modifiers of huntingtin proteolysis and toxicity in huntington\u2019s disease","volume":"67","author":"Miller","year":"2010","journal-title":"Neuron"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1073\/pnas.100110097","article-title":"The huntington\u2019s disease protein interacts with P53 and CREB-binding protein and represses transcription","volume":"97","author":"Steffan","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/hmg\/ddn139","article-title":"Activated caspase-6 and caspase-6-cleaved fragments of huntingtin specifically colocalize in the nucleus","volume":"17","author":"Warby","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.baga.2014.04.002","article-title":"Factors that contribute to balance and mobility impairments in individuals with Huntington\u2019s disease","volume":"4","author":"Cruickshank","year":"2014","journal-title":"Basal Ganglia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/ng1193-259","article-title":"Widespread expression of the human and rat Huntington\u2019s disease gene in brain and nonneural tissues","volume":"5","author":"Strong","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0896-6273(95)90345-3","article-title":"Widespread expression of Huntington\u2019s disease gene (IT15) protein product","volume":"14","author":"Sharp","year":"1995","journal-title":"Neuron"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ng0595-104","article-title":"Cellular localization of the Huntington\u2019s disease protein and discrimination of the normal and mutated form","volume":"10","author":"Trottier","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","article-title":"Formation of polyglutamine inclusions in non-CNS tissue","volume":"8","author":"Sathasivam","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/hmg\/11.17.1911","article-title":"Dysregulation of gene expression in the R6\/2 model of polyglutamine disease: Parallel changes in muscle and brain","volume":"11","author":"Hanson","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","article-title":"Huntington\u2019s disease: The current state of research with peripheral tissues","volume":"219","author":"Sassone","year":"2009","journal-title":"Exp. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/sj.cdd.4401967","article-title":"Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington\u2019s disease subjects","volume":"13","author":"Ciammola","year":"2006","journal-title":"Cell Death Differ."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bbrc.2008.07.009","article-title":"Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington\u2019s disease patients","volume":"374","author":"Almeida","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/mds.21550","article-title":"Myopathy as a first symptom of Huntington\u2019s disease in a marathon runner","volume":"22","author":"Kosinski","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1007\/s00415-008-0964-x","article-title":"Use of hand-held dynamometry in the evaluation of lower limb muscle strength in people with Huntington\u2019s disease","volume":"255","author":"Busse","year":"2008","journal-title":"J. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/jnnp.2003.017822","article-title":"Rate and correlates of weight change in Huntington\u2019s disease","volume":"75","author":"Hamilton","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/mds.21540","article-title":"Clinical correlates of mitochondrial function in Huntington\u2019s disease muscle","volume":"22","author":"Turner","year":"2007","journal-title":"Mov. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1474-4422(15)00177-5","article-title":"Treating the whole body in Huntington\u2019s disease","volume":"14","author":"Carroll","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","article-title":"Beyond the brain: Widespread pathology in Huntington\u2019s disease","volume":"8","author":"Brundin","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000072863","article-title":"The use of transgenic and knock-in mice to study Huntington\u2019s disease","volume":"100","author":"Hickey","year":"2003","journal-title":"Cytogenet. Genome Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0168-9525(01)02625-7","article-title":"Lessons from animal models of Huntington\u2019s disease","volume":"18","author":"Rubinsztein","year":"2002","journal-title":"Trends Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0165-6147(00)01884-8","article-title":"Mouse models of Huntington\u2019s disease","volume":"23","author":"Menalled","year":"2002","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1602\/neurorx.2.3.465","article-title":"Knock-in mouse models of Huntington\u2019s disease","volume":"2","author":"Menalled","year":"2005","journal-title":"NeuroRx"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0092-8674(00)81369-0","article-title":"Exon I of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice","volume":"87","author":"Mangiarini","year":"1996","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/hmg\/ddh175","article-title":"Nuclear-targeting of mutant huntingtin fragments produces huntington\u2019s disease-like phenotypes in transgenic mice","volume":"13","author":"Schilling","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/hmg\/8.3.397","article-title":"Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of Huntingtin","volume":"8","author":"Schilling","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/hmg\/8.7.1227","article-title":"Ultrastructural localization and progressive formation of neuropil aggregates in Huntington\u2019s disease transgenic mice","volume":"8","author":"Li","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0092-8674(00)80513-9","article-title":"Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation","volume":"90","author":"Davies","year":"1997","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1073\/pnas.1221891110","article-title":"Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease","volume":"110","author":"Sathasivam","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainresbull.2006.11.004","article-title":"The HdhQ150\/Q150 Knock-in mouse model of HD and the R6\/2 Exon 1 model develop comparable and widespread molecular phenotypes","volume":"72","author":"Woodman","year":"2007","journal-title":"Brain Res. Bull."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nbt0997-859","article-title":"Homologous recombination based modification in esherichia coli and germline transmission in transgenic mice of a bacterial artificial chromsome","volume":"15","author":"Yang","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1523\/JNEUROSCI.0857-08.2008","article-title":"Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice","volume":"28","author":"Gray","year":"2008","journal-title":"J. Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1093\/hmg\/5.12.1875","article-title":"Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype","volume":"5","author":"Hodgson","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0896-6273(00)80764-3","article-title":"A YAC mouse model for huntington\u2019s disease with full-length mutant Huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration","volume":"23","author":"Hodgson","year":"1999","journal-title":"Neuron"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1093\/hmg\/ddi407","article-title":"Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease","volume":"14","author":"Murphy","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3233\/JHD-130001","article-title":"A transgenic minipig model of Huntington\u2019s disease","volume":"2","author":"Baxa","year":"2013","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1212\/01.WNL.0000031791.10922.CF","article-title":"Weight loss in early stage of Huntington\u2019s disease","volume":"59","author":"Knowlton","year":"2002","journal-title":"Neurology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/j.1468-1331.2006.01319.x","article-title":"Weight Changes in Huntington\u2019s disease","volume":"13","author":"Robbins","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1212\/01.wnl.0000334276.09729.0e","article-title":"Weight loss in Huntington disease increases with higher CAG repeat number","volume":"71","author":"Aziz","year":"2008","journal-title":"Neurology"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Mochel, F., Charles, P., Seguin, F., Barritault, J., Coussieu, C., Perin, L., Le Bouc, Y., Gervais, C., Carcelain, G., and Vassault, A. (2007). Early energy deficit in huntingdon disease: Identification of a plasma biomarker traceable during disease progression. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000647"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1212\/WNL.0b013e3181b04aa2","article-title":"Dietary intake in adults at risk for Huntington disease: Analysis of PHAROS research participants","volume":"73","author":"Marder","year":"2009","journal-title":"Neurology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1212\/WNL.0b013e3182648b65","article-title":"Measures of growth in children at risk for Huntington disease","volume":"79","author":"Lee","year":"2012","journal-title":"Neurology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1111\/j.1460-9568.2004.03783.x","article-title":"Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington\u2019s disease mutation","volume":"20","author":"Ribchester","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nbd.2007.07.029","article-title":"Increased metabolism in the R6\/2 mouse model of Huntington\u2019s disease","volume":"29","author":"Bacos","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1152\/ajpendo.00630.2010","article-title":"Molecular characterization of skeletal muscle atrophy in the R6\/2 mouse model of Huntington\u2019s disease","volume":"301","author":"She","year":"2011","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2217\/nmt.13.22","article-title":"Characteristics, pathophysiology and clinical management of weight loss in Huntington\u2019s disease","volume":"3","author":"Aziz","year":"2013","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"43030","DOI":"10.1038\/srep43030","article-title":"Metabolic profiling of presymptomatic Huntington\u2019s disease sheep reveals novel biomarkers","volume":"7","author":"Skene","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"14275","DOI":"10.1038\/s41598-017-14290-3","article-title":"Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington\u2019s disease mice","volume":"7","author":"Bondulich","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1085\/jgp.201611603","article-title":"Progressive Cl-channel defects reveal disrupted skeletal muscle maturation in R6\/2 Huntington\u2019s mice","volume":"149","author":"Miranda","year":"2016","journal-title":"J. Gen. Physiol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Moffitt, H., McPhail, G.D., Woodman, B., Hobbs, C., and Bates, G.P. (2009). Formation of polyglutamine inclusions in a wide range of non-cns tissues in the HdhQ150 Knock-in mouse model of Huntington\u2019s disease. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0008025"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ana.25007","article-title":"Body weight is a robust predictor of clinical progression in Huntington disease","volume":"82","author":"Gardiner","year":"2017","journal-title":"Ann. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3233\/JHD-150152","article-title":"Abnormal weight and body mass index in children with juvenile Huntington\u2019s disease","volume":"4","author":"Tereshchenko","year":"2015","journal-title":"J. Huntington\u2019s Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Mielcarek, M., Toczek, M., Smeets, C.J.L.M., Franklin, S.A., Bondulich, M.K., Jolinon, N., Muller, T., Ahmed, M., Dick, J.R.T., and Piotrowska, I. (2015). HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. PLoS Genet., 11.","DOI":"10.1371\/journal.pgen.1005021"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/hmg\/ddi192","article-title":"Gene expression in Huntington\u2019s disease skeletal muscle: A potential biomarker","volume":"14","author":"Strand","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15983","DOI":"10.1073\/pnas.252625599","article-title":"AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation","volume":"99","author":"Zong","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1093\/hmg\/ddp243","article-title":"Impaired PGC-1\u03b1 function in muscle in Huntington\u2019s disease","volume":"18","author":"Chaturvedi","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nbd.2009.05.007","article-title":"Systematic behavioral evaluation of Huntington\u2019s disease transgenic and knock-in mouse models","volume":"35","author":"Menalled","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1093\/hmg\/ddw050","article-title":"Motor deficits associated with Huntington\u2019s disease occur in the absence of striatal degeneration in BACHD transgenic mice","volume":"25","author":"Mantovani","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Valad\u00e3o, P.A.C., de Arag\u00e3o, B.C., Andrade, J.N., Magalh\u00e3es-Gomes, M.P.S., Foureaux, G., Joviano-Santos, J.V., Nogueira, J.C., Machado, T.C.G., de Jesus, I.C.G., and Nogueira, J.M. (2019). Abnormalities in the motor unit of a fast-twitch lower limb skeletal muscle in Huntington\u2019s disease. ASN Neuro, 11.","DOI":"10.1177\/1759091419886212"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1085\/jgp.201411255","article-title":"Altered Ca2+ signaling in skeletal muscle fibers of the R6\/2 mouse, a model of Huntington\u2019s disease","volume":"144","author":"Braubach","year":"2014","journal-title":"J. Gen. Physiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1113\/jphysiol.2012.243279","article-title":"Ca2+-dependent proteolysis of junctophilin-1 and junctophilin-2 in skeletal and cardiac muscle","volume":"591","author":"Murphy","year":"2013","journal-title":"J. Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/mds.20373","article-title":"Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington\u2019s disease","volume":"20","author":"Saft","year":"2005","journal-title":"Mov. Disord."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.chembiol.2011.12.020","article-title":"TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant Huntingtin in huntington\u2019s disease","volume":"19","author":"Baldo","year":"2012","journal-title":"Chem. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3233\/JHD-180324","article-title":"Huntingtin aggregates and mitochondrial pathology in skeletal muscle but not heart of late-stage R6\/2 mice","volume":"8","author":"Kojer","year":"2019","journal-title":"J. Huntington\u2019s. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1084\/jem.20160776","article-title":"Potential biomarkers to follow the progression and treatment response of Huntington\u2019s disease","volume":"213","author":"Disatnik","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"13896","DOI":"10.1038\/s41598-017-13713-5","article-title":"Ghrelin rescues skeletal muscle catabolic profile in the R6\/2 mouse model of Huntington\u2019s disease","volume":"7","author":"Duarte","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00401-020-02156-4","article-title":"MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease","volume":"140","author":"Nath","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2003.02009.x","article-title":"Inclusion formation in Huntington\u2019s disease R6\/2 mouse muscle cultures","volume":"87","author":"Orth","year":"2003","journal-title":"J. Neurochem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/j.celrep.2019.02.008","article-title":"Unbiased profiling of isogenic Huntington disease HPSC-derived CNS and peripheral cells reveals strong cell-type specificity of CAG length effects","volume":"26","author":"Ooi","year":"2019","journal-title":"Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"MTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13395-016-0086-6","article-title":"The beneficial role of proteolysis in skeletal muscle growth and stress adaptation","volume":"6","author":"Bell","year":"2016","journal-title":"Skelet. Muscle"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Vainshtein, A., and Sandri, M. (2020). Signaling pathways that control muscle mass. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134759"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Scalabrin, M., Adams, V., Labeit, S., and Bowen, T.S. (2020). Emerging strategies targeting catabolic muscle stress relief. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134681"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"101078","DOI":"10.1016\/j.arr.2020.101078","article-title":"Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies","volume":"61","author":"Kumar","year":"2020","journal-title":"Ageing Res Rev."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"583","DOI":"10.18632\/aging.101181","article-title":"Changes in macroautophagy, chaperone-mediated autophagy, and mitochondrial metabolism in murine skeletal and cardiac muscle during aging","volume":"9","author":"Zhou","year":"2017","journal-title":"Aging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1113\/JP275998","article-title":"Autophagy and mitophagy flux in young and aged skeletal muscle following chronic contractile activity","volume":"596","author":"Carter","year":"2018","journal-title":"J. Physiol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2017.03.009","article-title":"Skeletal muscle autophagy and its role in sarcopenia and organismal aging","volume":"34","author":"Jiao","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.bbamcr.2016.12.015","article-title":"Effect of acute and chronic autophagy deficiency on skeletal muscle apoptotic signaling, morphology, and function","volume":"1864","author":"Baechler","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cmet.2007.11.004","article-title":"FoxO3 coordinately activates protein degradation by the autophagic\/lysosomal and proteasomal pathways in atrophying muscle cells","volume":"6","author":"Zhao","year":"2007","journal-title":"Cell Metab."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0092-8674(04)00400-3","article-title":"Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy","volume":"117","author":"Sandri","year":"2004","journal-title":"Cell"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.cmet.2007.11.001","article-title":"FoxO3 controls autophagy in skeletal muscle in vivo","volume":"6","author":"Mammucari","year":"2007","journal-title":"Cell Metab."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"27068","DOI":"10.1074\/jbc.M113.486076","article-title":"Expanded polyglutamine-containing n-terminal Huntingtin fragments are entirely degraded by mammalian proteasomes","volume":"288","author":"Juenemann","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/sj.emboj.7600426","article-title":"Inefficient degradation of truncated polyglutamine proteins by the proteasome","volume":"23","author":"Holmberg","year":"2004","journal-title":"EMBO J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"16889","DOI":"10.1073\/pnas.1420103111","article-title":"Potential function for the huntingtin protein as a scaffold for selective autophagy","volume":"111","author":"Ochaba","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/ncb3101","article-title":"Huntingtin functions as a scaffold for selective macroautophagy","volume":"17","author":"Rui","year":"2015","journal-title":"Nat. Cell Biol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1080\/15548627.2015.1039219","article-title":"HTT\/Huntingtin in selective autophagy and Huntington disease: A foe or a friend within?","volume":"11","author":"Rui","year":"2015","journal-title":"Autophagy"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.15252\/embj.201490808","article-title":"Huntingtin proteolysis releases non-polyq fragments that cause toxicity through dynamin 1 dysregulation","volume":"34","author":"Hangen","year":"2015","journal-title":"EMBO J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2014.09.003","article-title":"Autophagy in Huntington disease and huntingtin in autophagy","volume":"38","author":"Martin","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2044-5040-3-6","article-title":"Differential response of skeletal muscles to MTORC1 signaling during atrophy and hypertrophy","volume":"3","author":"Bentzinger","year":"2013","journal-title":"Skelet. Muscle"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1242\/dmm.019414","article-title":"The Role of MTOR Signaling in the regulation of protein synthesis and muscle mass during immobilization in mice","volume":"8","author":"You","year":"2015","journal-title":"DMM Dis. Model. Mech."},{"key":"ref_111","first-page":"ra18","article-title":"MTORC1 promotes denervation-induced muscle atrophy through a mechanism involving the activation of FoxO and E3 ubiquitin ligases","volume":"7","author":"Tang","year":"2014","journal-title":"Sci. Sign."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"113396","DOI":"10.1016\/j.expneurol.2020.113396","article-title":"Compromised IGF signaling causes caspase-6 activation in Huntington disease","volume":"332","author":"Skotte","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1093\/hmg\/ddq026","article-title":"Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression","volume":"19","author":"Pouladi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3018584","DOI":"10.1155\/2019\/3018584","article-title":"Increased circulating levels of interleukin-6 affect the redox balance in skeletal muscle","volume":"2019","author":"Forcina","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"C372","DOI":"10.1152\/ajpcell.00293.2006","article-title":"Role for I\u03baB\u03b1, but not c-Rel, in skeletal muscle atrophy","volume":"292","author":"Judge","year":"2007","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1172\/JCI28721","article-title":"Erratum: Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration","volume":"116","author":"Mourkioti","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JHD-130075","article-title":"Skeletal muscle atrophy in R6\/2 mice-altered circulating skeletal muscle markers and gene expression profile changes","volume":"3","author":"Davidsson","year":"2014","journal-title":"J. Huntington\u2019s. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1172\/JCI68523","article-title":"NF-\u039aB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia","volume":"123","author":"He","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington\u2019s disease","volume":"205","author":"Wild","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5766","DOI":"10.1210\/jc.2003-030604","article-title":"Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): The longitudinal aging study Amsterdam","volume":"88","author":"Visser","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/gerona\/glp097","article-title":"Higher inflammatory marker levels in older persons: Associations with 5-year change in muscle mass and muscle strength","volume":"64","author":"Schaap","year":"2009","journal-title":"J. Gerontol. Ser. A Biol. Sci. Med. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Stewart, R., Flechner, L., Montminy, M., and Berdeaux, R. (2011). Creb Is activated by muscle injury and promotes muscle regeneration. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024714"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/hmg\/ddt458","article-title":"P53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin","volume":"23","author":"Ehrnhoefer","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ana.410410206","article-title":"Energy metabolism defects in Huntington\u2019s disease and effects of coenzyme Q10","volume":"41","author":"Koroshetz","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/1531-8249(200007)48:1<72::AID-ANA11>3.0.CO;2-I","article-title":"Abnormal in vivo skeletal muscle energy metabolism in Huntington\u2019s disease and dentatorubropallidoluysian atrophy","volume":"48","author":"Lodi","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.23258","article-title":"Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington\u2019s disease","volume":"26","author":"Ciammola","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1007\/s12035-017-0503-9","article-title":"Mitochondrial quality control and disease: Insights into ischemia-reperfusion injury","volume":"55","author":"Anzell","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.emboj.7601963","article-title":"Fission and selective fusion govern mitochondrial segregation and elimination by autophagy","volume":"27","author":"Twig","year":"2008","journal-title":"EMBO J."},{"key":"ref_129","first-page":"a011072","article-title":"Mechanisms of mitochondrial fission and fusion","volume":"5","author":"Shen","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"R170","DOI":"10.1016\/j.cub.2018.01.004","article-title":"Mitophagy and quality control mechanisms in mitochondrial maintenance","volume":"28","author":"Pickles","year":"2018","journal-title":"Curr. Biol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.cellbio.22.010305.104638","article-title":"Mitochondrial fusion and fission in mammals","volume":"22","author":"Chan","year":"2006","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1042\/EBC20170104","article-title":"Mitochondrial dynamics: Overview of molecular mechanisms","volume":"62","author":"Tilokani","year":"2018","journal-title":"Essays Biochem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cell.2010.02.026","article-title":"Mitochondrial fusion is required for mtdna stability in skeletal muscle and tolerance of MtDNA mutations","volume":"141","author":"Chen","year":"2010","journal-title":"Cell"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cmet.2017.04.021","article-title":"Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence","volume":"25","author":"Tezze","year":"2017","journal-title":"Cell Metab."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.15252\/embj.201593084","article-title":"Mfn2 deficiency links age-related sarcopenia and impaired autophagy to activation of an adaptive mitophagy pathway","volume":"35","author":"Sorianello","year":"2016","journal-title":"EMBO J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/emboj.2010.60","article-title":"Mitochondrial fission and remodelling contributes to muscle atrophy","volume":"29","author":"Romanello","year":"2010","journal-title":"EMBO J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e1663","DOI":"10.1038\/cddis.2014.595","article-title":"Muscle-specific Drp1 overexpression impairs skeletal muscle growth via translational attenuation","volume":"6","author":"Touvier","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1038\/s41467-019-10226-9","article-title":"DRP1-mediated mitochondrial shape controls calcium homeostasis and muscle mass","volume":"10","author":"Favaro","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.molmet.2018.11.012","article-title":"The impact of exercise on mitochondrial dynamics and the role of Drp1 in exercise performance and training adaptations in skeletal muscle","volume":"21","author":"Moore","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1113\/JP279802","article-title":"Drp1 knockdown induces severe muscle atrophy and remodelling, mitochondrial dysfunction, autophagy impairment and denervation","volume":"598","author":"Dulac","year":"2020","journal-title":"J. Physiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nm.2313","article-title":"Mutant huntingtin binds the mitochondrial fission","volume":"17","author":"Song","year":"2011","journal-title":"Nat. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1093\/hmg\/ddr024","article-title":"Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington\u2019s disease: Implications for selective neuronal damage","volume":"20","author":"Shirendeb","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/hmg\/ddr475","article-title":"Mutant huntingtin\u2019s interaction with mitochondrial protein drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington\u2019s disease","volume":"21","author":"Shirendeb","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.410430321","article-title":"Complex I defect in muscle from patients with Huntington\u2019s disease","volume":"43","author":"Arenas","year":"1998","journal-title":"Ann. Neurol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00702-009-0328-4","article-title":"Abnormal morphology of peripheral cell tissues from patients with Huntington disease","volume":"117","author":"Squitieri","year":"2010","journal-title":"J. Neural Transm."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/hmg\/ddr541","article-title":"Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington\u2019s disease","volume":"21","author":"Johri","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.20754","article-title":"Low stability of huntington muscle mitochondria against Ca 2+ in R6\/2 mice","volume":"59","author":"Gizatullina","year":"2006","journal-title":"Ann. Neurol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"dmm038737","DOI":"10.1242\/dmm.038737","article-title":"Deterioration of mitochondrial bioenergetics and ultrastructure impairment in skeletal muscle of a transgenic minipig model in the early stages of Huntington\u2019s disease","volume":"12","author":"Rodinova","year":"2019","journal-title":"DMM Dis. Model. Mech."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0175248","article-title":"High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington\u2019s disease expansion mutation carriers shows normal mitochondrial respiratory function","volume":"12","author":"Buck","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K","article-title":"Mitochondrial dysfunction and free radical damage in the huntington R6\/2 transgenic mouse","volume":"47","author":"Tabrizi","year":"2000","journal-title":"Ann. Neurol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nature00904","article-title":"Transcriptional Co-activator PGC-1\u03b1 drives the formation of slow-twitch muscle fibres","volume":"418","author":"Lin","year":"2002","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cell.2004.09.013","article-title":"Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1\u03b1 null mice","volume":"119","author":"Lin","year":"2004","journal-title":"Cell"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"0672","DOI":"10.1371\/journal.pbio.0030101","article-title":"PGC-1\u03b1 deficiency causes multi-system energy metabolic derangements: Muscle dysfunction, abnormal weight control and hepatic steatosis","volume":"3","author":"Leone","year":"2005","journal-title":"PLoS Biol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/(SICI)1097-4598(200005)23:5<661::AID-MUS3>3.0.CO;2-J","article-title":"Myosin heavy chain isoform expression following reduced neuromuscular activity: Potential regulatory mechanisms","volume":"23","author":"Talmadge","year":"2000","journal-title":"Muscle Nerve"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1152\/physrev.00031.2010","article-title":"Fiber types in mammalian skeletal muscles","volume":"91","author":"Schiaffino","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0248-4900(03)00087-X","article-title":"Myosin heavy chain isoforms in postnatal muscle development of mice","volume":"95","author":"Agbulut","year":"2003","journal-title":"Biol. Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/BFb0036123","article-title":"Adaptation of mammalian skeletal muscle fibers to chronic electrical stimulation","volume":"120","author":"Pette","year":"1992","journal-title":"Rev. Physiol. Biochem. Pharmacol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Hering, T., Braubach, P., Landwehrmeyer, G.B., Lindenberg, K.S., and Melzer, W. (2016). Fast-to-slow transition of skeletal muscle contractile function and corresponding changes in myosin heavy and light chain formation in the R6\/2 mouse model of Huntington\u2019s disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166106"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1523\/JNEUROSCI.2011-10.2011","article-title":"Increased neurotransmitter release at the neuromuscular junction in a mouse model of polyglutamine disease","volume":"31","author":"Rozas","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tig.2004.01.008","article-title":"Huntingtin-protein interactions and the pathogenesis of huntington\u2019s disease","volume":"20","author":"Li","year":"2004","journal-title":"Trends Genet."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuron.2007.11.025","article-title":"Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm","volume":"57","author":"Romero","year":"2008","journal-title":"Neuron"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"8077","DOI":"10.1523\/JNEUROSCI.0313-17.2017","article-title":"Depressed synaptic transmission and reduced vesicle release sites in Huntington\u2019s disease neuromuscular junctions","volume":"37","author":"Khedraki","year":"2017","journal-title":"J. Neurosci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuint.2015.12.013","article-title":"Changes in structure and function of diaphragm neuromuscular junctions from BACHD mouse model for Huntington\u2019s disease","volume":"93","author":"Rodrigues","year":"2016","journal-title":"Neurochem. Int."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"9160","DOI":"10.1073\/pnas.1220068110","article-title":"Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction","volume":"110","author":"Waters","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"C218","DOI":"10.1152\/ajpcell.00153.2020","article-title":"Mechanisms of altered skeletal muscle action potentials in the R6\/2 mouse model of Huntington\u2019s disease","volume":"319","author":"Miranda","year":"2020","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainres.2007.06.059","article-title":"Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington\u2019s disease mutation","volume":"1188","author":"Wade","year":"2008","journal-title":"Brain Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/ejn.13510","article-title":"Muscle atrophy is associated with cervical spinal motoneuron loss in BACHD mouse model for Huntington\u2019s disease","volume":"45","author":"Andrade","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"A97-A97","DOI":"10.1136\/jnnp-2014-309032.281","article-title":"M09 myostatin inhibition as a novel approach to targeting muscle pathology in HD","volume":"85","author":"Mielcarek","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in huntington disease: From current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet. Part A"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Dash, D., and Mestre, T.A. (2020). Therapeutic update on Huntington\u2019s disease: Symptomatic treatments and emerging disease-modifying therapies. Neurotherapeutics.","DOI":"10.1007\/s13311-020-00891-w"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"9306","DOI":"10.1073\/pnas.151270098","article-title":"Regulation of myostatin activity and muscle growth","volume":"98","author":"Lee","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-\u03b2 superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"ref_174","unstructured":"F\u00e3o, L., and Rego, A.C. (2020). Mitochondrial and redox-based therapeutic strategies in Huntington\u2019s disease. Antioxid. Redox Sign., 1\u201324."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"8892","DOI":"10.1073\/pnas.95.15.8892","article-title":"Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects","volume":"95","author":"Matthews","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington\u2019s disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci. Lett."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington\u2019s disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Menalled, L.B., Patry, M., Ragland, N., Lowden, P.A.S., Goodman, J., Minnich, J., Zahasky, B., Park, L., Leeds, J., and Howland, D. (2010). Comprehensive behavioral testing in the R6\/2 mouse model of Huntington\u2019s disease shows no benefit from CoQ10 or minocycline. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009793"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington\u2019s disease: A placebo-controlled pilot trial","volume":"61","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1212\/01.wnl.0000169025.09670.6d","article-title":"Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial","volume":"65","author":"Puri","year":"2005","journal-title":"Neurology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/jnc.13553","article-title":"Laquinimod Dampens hyperactive cytokine production in Huntington\u2019s disease patient myeloid cells","volume":"137","author":"Dobson","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-04990-1","article-title":"Laquinimod treatment in the R6\/2 mouse model","volume":"7","author":"Ellrichmann","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2015.01.002","article-title":"Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease","volume":"76","author":"Southwell","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00337","article-title":"Immunotherapies in Huntington\u2019s disease and \u03b1-synucleinopathies","volume":"11","author":"Fatoba","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1750-1326-5-18","article-title":"Tetrabenazine is neuroprotective in Huntington\u2019s disease mice","volume":"5","author":"Wang","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","article-title":"Current pharmacological approaches to reduce chorea in Huntington\u2019s disease","volume":"77","author":"Coppen","year":"2017","journal-title":"Drugs"},{"key":"ref_188","first-page":"123","article-title":"Management of Huntington\u2019s disease: Role of tetrabenazine","volume":"7","author":"Serpino","year":"2011","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","article-title":"Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease","volume":"4","author":"Claassen","year":"2017","journal-title":"J. Clin. Mov. Disord."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fmolb.2019.00020","article-title":"Protein misfolding and ER stress in Huntington\u2019s disease","volume":"6","author":"Shacham","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.1093\/hmg\/ddv335","article-title":"Transcriptional dysregulation of inflammatory\/immune pathways after active vaccination against Huntington\u2032s disease","volume":"24","author":"Ramsingh","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1525-0016(03)00063-7","article-title":"DNA vaccination against mutant huntingtin ameliorates the HDR6\/2 diabetic phenotype","volume":"7","author":"Miller","year":"2003","journal-title":"Mol. Ther."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","article-title":"Recent Advances in the treatment of Huntington\u2019s disease: Targeting DNA and RNA","volume":"34","author":"Shannon","year":"2020","journal-title":"CNS Drugs"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-pharmtox-010716-104846","article-title":"Pharmacology of antisense drugs","volume":"57","author":"Bennett","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/dna.2019.5188","article-title":"Therapeutic antisense targeting of huntingtin","volume":"39","author":"Smith","year":"2020","journal-title":"DNA Cell Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8314\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:29:55Z","timestamp":1760178595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/8314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,5]]},"references-count":195,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21218314"],"URL":"https:\/\/doi.org\/10.3390\/ijms21218314","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,5]]}}}